Abstract
In the absence of effective treatment, infection with the human immunodeficiency virus (HIV) ultimately leads to the acquired immune deficiency syndrome (AIDS). Many attempts have been made to prevent and attenuate HIV infection. While antiretroviral therapies for infected individuals have had great success, preventative and therapeutic vaccines focused on both humoral and cell-mediated immunity have failed. Recently, several natural killer cell receptor (NKR) genotypes, in concert with certain class I human histompatibility-linked antigens (HLA) were found to be associated with protection from HIV infection and/or disease progression. These receptors are expressed on both natural killer (NK) cells and subsets of T lymphocytes. As HIV infection is often associated with attenuation of NK cells and much remains unknown about the basic functions of NKR, it remains undetermined whether the protective effect of these receptors relates to their expression on NK cells, T lymphocytes or both. This review summarizes current literature regarding NKR and HIV infection, and addresses several major questions remaining about the role of these receptors in protection against infection and disease progression.
Keywords: NK cells, HIV, T lymphocytes, NK receptors, AIDS
Current HIV Research
Title: Natural Killer Cell Receptors in Human Immunodeficiency Virus Infection: Pathways to Protection or Doors to Disappointment?
Volume: 7 Issue: 5
Author(s): Matthew S. Parsons and Michael Grant
Affiliation:
Keywords: NK cells, HIV, T lymphocytes, NK receptors, AIDS
Abstract: In the absence of effective treatment, infection with the human immunodeficiency virus (HIV) ultimately leads to the acquired immune deficiency syndrome (AIDS). Many attempts have been made to prevent and attenuate HIV infection. While antiretroviral therapies for infected individuals have had great success, preventative and therapeutic vaccines focused on both humoral and cell-mediated immunity have failed. Recently, several natural killer cell receptor (NKR) genotypes, in concert with certain class I human histompatibility-linked antigens (HLA) were found to be associated with protection from HIV infection and/or disease progression. These receptors are expressed on both natural killer (NK) cells and subsets of T lymphocytes. As HIV infection is often associated with attenuation of NK cells and much remains unknown about the basic functions of NKR, it remains undetermined whether the protective effect of these receptors relates to their expression on NK cells, T lymphocytes or both. This review summarizes current literature regarding NKR and HIV infection, and addresses several major questions remaining about the role of these receptors in protection against infection and disease progression.
Export Options
About this article
Cite this article as:
Parsons S. Matthew and Grant Michael, Natural Killer Cell Receptors in Human Immunodeficiency Virus Infection: Pathways to Protection or Doors to Disappointment?, Current HIV Research 2009; 7 (5) . https://dx.doi.org/10.2174/157016209789346273
DOI https://dx.doi.org/10.2174/157016209789346273 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Gene Expression by TDP-43 and FUS/TLS in Frontotemporal Lobar Degeneration
Current Alzheimer Research Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development
Current Cancer Drug Targets The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Molecular Mechanisms of Thymoquinone as Anticancer Agent
Combinatorial Chemistry & High Throughput Screening Applied Proteomics in Companion Animal Medicine
Current Proteomics Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation
Current HIV Research Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry Kefir: A Synbiotic with Approved Anticarcinogenic Properties
Current Bioactive Compounds